Beam Therapeutics (NASDAQ:BEAM) Upgraded at Canaccord Genuity Group
Canaccord Genuity Group has upgraded Beam Therapeutics (NASDAQ:BEAM) to a "strong-buy" rating, contributing to a consensus "Moderate Buy" rating among analysts with an average target price of $45.69. The gene-editing company's stock has seen recent trading activity, including an insider sale by Christine Bellon in January, and significant institutional investor interest. Beam Therapeutics, known for its pioneering base editing platform, aims to develop precision genetic medicines.
Beam base editing therapy gets ‘proof of concept’ in rare lung disease
Beam Therapeutics has presented initial positive results from a small clinical trial for its base-editing therapy, BEAM-302, targeting the rare lung and liver disorder alpha-1 antitrypsin deficiency (AATD). The therapy, designed to directly correct a disease-causing genetic mutation, showed increased levels of properly produced AAT protein and reduced misfolded protein in patients. Despite these promising "proof of concept" findings, Beam's shares initially fell, highlighting ongoing challenges in genetic medicine development, even as the company secured an additional $500 million in funding to extend its financial runway.
Canaccord Genuity Initiates Coverage on BEAM with a 'Buy' Rating
Canaccord Genuity has initiated coverage on Beam Therapeutics (BEAM) with a 'Buy' rating and a price target of $74.00 USD. This comes amidst varied analyst opinions, with other firms like Bernstein and HC Wainwright & Co. also maintaining positive ratings, while UBS and Evercore ISI Group have provided "Neutral" and "Outperform" ratings respectively. The average target price from 16 analysts is $46.52, suggesting a 68.61% upside from its current price of $27.59, though GuruFocus estimates a potential downside based on its GF Value.
Canaccord Genuity initiates Beam Therapeutics stock with buy rating
Canaccord Genuity has initiated coverage on Beam Therapeutics (NASDAQ:BEAM) with a "buy" rating and a $74.00 price target, citing its late clinical stage, near-term catalysts, and strong execution track record. The firm highlighted Beam's progress with clinical data, successful spin-out acquisitions, and plans for regulatory submissions. Despite Beam's stock underperforming the Nasdaq Biotechnology Index in 2025, it has shown significant momentum in recent months, with analysts largely maintaining a "strong buy" consensus.
Canaccord Genuity initiates Beam Therapeutics stock with buy rating
Canaccord Genuity initiated coverage on Beam Therapeutics (NASDAQ:BEAM) with a buy rating and a $74.00 price target, citing its late clinical stage, near-term catalysts, and capital for its first launch. The research firm highlighted the company's strong execution track record, including positive clinical data and strategic collaborations. Other analysts also show optimism, with Bernstein, H.C. Wainwright, and Cantor Fitzgerald maintaining positive ratings, while UBS initiated coverage with a Neutral rating.
Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory
William Blair analyst Sami Corwin maintained a Buy rating on Beam Therapeutics (BEAM), emphasizing the strong clinical data for its lead program, BEAM-302, targeting alpha-1 antitrypsin deficiency. The analyst highlighted the upcoming clinical data update in early 2026 as a key catalyst and noted the FDA's alignment on a potential accelerated approval pathway, which de-risks the regulatory route. This positive outlook is further supported by strengthening clinical evidence and defined milestones, reinforcing the bullish stance on the company.
Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory
An analyst from William Blair has maintained a Buy rating on Beam Therapeutics (BEAM), citing confidence in the trajectory of its lead drug program, BEAM-302, for alpha-1 antitrypsin deficiency. The analyst highlighted strengthening clinical evidence, regulatory alignment with the FDA on an accelerated approval pathway, and upcoming clinical data updates as key catalysts. This positive outlook is based on the company's progress in precision genetic medicines and its regulatory strategy.
13 Hot Stocks to Buy with the Highest Upside Potential
This article identifies 13 hot stocks with high upside potential, highlighting Beam Therapeutics Inc. (NASDAQ: BEAM) as one example. An analyst from William Blair maintained a Buy rating on Beam, citing positive clinical data for its lead program and a clear regulatory pathway. The company is a biotechnology firm focused on precision genetic medicines.
Here is Why Beam Therapeutics (BEAM) Appears so Attractive
Beam Therapeutics (BEAM) is highlighted as an attractive biotechnology stock with significant upside potential, primarily due to positive analyst ratings and clinical advancements. H.C. Wainwright maintained a Buy rating with a high price target, citing FDA expediting approval for BEAM-302 and the company's strong financial position. While another analyst gave a Neutral rating, the article emphasizes Beam's leadership in CRISPR-based gene editing and its promising pipeline.
Here is Why Beam Therapeutics (BEAM) Appears so Attractive
Beam Therapeutics (NASDAQ:BEAM) is highlighted as an attractive biotechnology stock with significant upside potential, primarily due to positive analyst ratings and clinical progress. H.C. Wainwright maintained a Buy rating with an $80 price target, citing FDA expediting BEAM-302 approval and strong financial standing. While UBS gave a Neutral rating, the article emphasizes Beam's leadership in CRISPR-based editing and ongoing gene therapy research.
Assessing Beam Therapeutics (BEAM) Valuation After New Patent Agreement Secures Base Editing IP Access
Beam Therapeutics (BEAM) recently secured a key patent agreement for its base editing intellectual property, which is central to its therapeutic approach. Despite a positive short-term share price performance, the company has seen weaker long-term returns. The article discusses a narrative suggesting Beam is significantly undervalued based on its advanced gene-editing technology and clinical milestones, contrasting this with market ratios that indicate high valuation risk.
H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval
H.C. Wainwright reaffirmed a Buy rating and an $80 price target for Beam Therapeutics (BEAM) after the company announced an expedited approval process for its BEAM-302 therapy with the FDA for alpha-1 antitrypsin deficiency (AATD). Beam Therapeutics plans to enroll 50 more patients in its Phase 1/2 trial to support the filing and anticipates reporting new data by late Q1 2026. The company ended 2025 with $1.25 billion in cash, extending its financial runway beyond 2029, which will fund the development of BEAM-302 and the launch of risto-cel.
Beam Therapeutics Secures Standby License for Key Patents
Beam Therapeutics has entered into a standby license agreement with Kobe University and Bio Palette Co., Ltd. to ensure continued access to key gene-editing patents. This arrangement safeguards Beam's intellectual property and reduces licensing risk associated with its base-editing programs. Despite weak financial performance, the company aims to strengthen its IP position for stakeholders.
Beam Therapeutics (BEAM) Is Up 8.9% After Securing Standby Gene-Editing IP License And Board Change
Beam Therapeutics (BEAM) saw an 8.9% increase after securing a standby gene-editing IP license with Kobe University and Bio Palette Co., Ltd., ensuring continued access to critical gene-editing patents. This move, coupled with an orderly board transition following a resignation, aims to alleviate licensing concerns and bolster confidence in the company's platform. The article notes that while the IP license strengthens the company's foundation, investors should continue to focus on clinical data readouts and managing toxicity risks in sickle cell disease for their base-editing programs.
Wedbush Remains a Buy on Beam Therapeutics (BEAM)
Wedbush reiterated a Buy rating on Beam Therapeutics (BEAM) with a price target of $57.00. This comes despite a recent Hold rating from TipRanks – Google. The company reported a Q3 revenue of $9.7 million and a GAAP net loss of $112.73 million.
Prime Editing and CRISPR Market Set for Explosive Growth at 24.1%
The global Prime Editing and CRISPR Market is projected to grow at a CAGR of 24.1% between 2024 and 2031, driven by advancements in gene editing therapies, expanding applications in various diseases, and increased investments. North America leads the market with a 34.5% share, while Asia Pacific shows the fastest growth. Key players include Beam Therapeutics, GenScript Biotech, and Thermo Fisher Scientific, with ongoing developments in therapeutic applications, agricultural innovation, and strategic acquisitions shaping the industry.
Understanding Momentum Shifts in (BEAM)
This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM) using AI models, highlighting divergent sentiment across different time horizons and suggesting choppy market conditions. It provides three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis detailing support and resistance levels. The report also mentions an exceptional short setup targeting significant downside with minimal risk.
FMR LLC's Strategic Acquisition of Beam Therapeutics Inc. Shares
FMR LLC, known as Fidelity, has significantly increased its stake in Beam Therapeutics Inc. by acquiring 12,750,369 shares at $27.72 each. This acquisition highlights FMR LLC's focus on growth within the biotechnology sector, despite Beam Therapeutics being considered overvalued with a GF Score of 48/100 and facing profitability and growth challenges. The transaction demonstrates FMR LLC's confidence in Beam Therapeutics' innovative genetic medicines, while also presenting both opportunities and risks for investors due to the company's current financial metrics and market valuation.
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Biotech Innovator with 73% Potential Upside
Beam Therapeutics Inc. (BEAM) is a biotechnology company focused on genetic medicine for severe diseases, showing a promising 73% potential upside according to analysts, despite not yet achieving profitability. The company faces financial challenges like negative revenue growth and cash flow but is buoyed by strong investor sentiment and strategic collaborations with pharmaceutical giants. Its innovative pipeline for genetic therapies presents a high-risk, high-reward opportunity for investors in the biotech sector.
Beam Therapeutics Meets 80-Plus Relative Strength Rating Benchmark
Beam Therapeutics (BEAM) has achieved a Relative Strength (RS) Rating of 84, surpassing the benchmark of 80, which indicates strong technical performance compared to other stocks. This news follows a recent surge in Beam's stock price after the company secured a deal with the FDA for its gene-editing drug. Investors often look for stocks with an RS Rating of 80 or higher as a sign of market leadership and potential investment opportunities.
Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to Sell
Wall Street Zen has downgraded Beam Therapeutics (NASDAQ:BEAM) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with a $43.80 price target. The company is trading around $26.52 with a $2.69 billion market cap, and insider Christine Bellon recently sold 1,371 shares. Institutional ownership is very high at 99.68%, with major firms like ARK Investment Management and Farallon Capital Management increasing their positions.
IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 188,243 Shares of Beam Therapeutics Inc. $BEAM
IQ EQ FUND MANAGEMENT IRELAND Ltd significantly increased its stake in Beam Therapeutics Inc. by 96.4% in Q3, purchasing 188,243 shares to own a total of 383,531 shares valued at $9.31 million. Concurrently, insider Christine Bellon sold 18,629 shares for approximately $644,750, reducing her holdings. Analysts maintain a "Moderate Buy" rating for Beam Therapeutics with an average target price of $43.80, despite the company missing recent quarterly EPS estimates.
Director Carole Ho to leave Beam Therapeutics (NASDAQ: BEAM) board
Beam Therapeutics Inc. reported that Carole Ho has submitted her resignation from the company’s Board of Directors, effective February 27, 2026. This voluntary board change was communicated via an 8-K filing and did not result from any disagreements regarding Beam's operations, policies, or practices. The company has a short transition period to adjust its board composition following this change.
Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases
Beam Therapeutics (BEAM) is advancing its BEAM-101 and BEAM-302 programs, targeting hematology and liver genetic diseases, with analysts raising price targets due to FDA alignment and upcoming data. While bullish sentiments focus on pipeline execution and a stake in Orbital Therapeutics, cautious analysts highlight execution risks, busulfan toxicity, and competitive pressures. The company reported positive safety and efficacy data from its BEACON trial for risto cel in sickle cell disease, showing efficient cell collection and significant improvements in hemoglobin levels.
Beam Therapeutics: A Critical Year for Clinical Validation
Beam Therapeutics is entering a critical period with several clinical and regulatory milestones anticipated in 2026 for its base-editing platform. Key updates include an accelerated approval pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency, a planned BLA submission for risto-cel in sickle cell disease, and initial data from a Phase 1/2 trial for BEAM-301. These developments, along with upcoming financial results, are expected to drive investor attention and potentially influence the stock's performance.
Is Beam Therapeutics’ (BEAM) Alpha-1 Update Quietly Reframing the Story of Its Gene-Editing Platform?
Beam Therapeutics (BEAM) recently received a favorable regulatory update for its Alpha-1 Antitrypsin Deficiency program, BEAM-302, which is now flagged as a key 2026 catalyst. This development, along with ARK Investment Management's share purchase and Bernstein's positive stance, is refocusing the market's attention on the potential of Beam's gene-editing platform. Despite an insider stock sale, the news highlights the growing importance of BEAM-302 alongside BEAM-101 in sickle cell disease, though the company remains loss-making and has a rich valuation.
Y Intercept Hong Kong Ltd Takes Position in Beam Therapeutics Inc. $BEAM
Y Intercept Hong Kong Ltd has initiated a new position in Beam Therapeutics Inc. (NASDAQ:BEAM), acquiring over 43,000 shares valued at approximately $1.059 million in Q3. This investment comes as other institutional investors have also adjusted their holdings in BEAM. The company recently reported earnings that missed analyst estimates, showing a negative EPS of ($1.10) and a revenue decline of 32.2% year-over-year, alongside an insider sale by Christine Bellon.
Avoiding Lag: Real-Time Signals in (BEAM) Movement
This article provides a real-time analysis of Beam Therapeutics Inc. (NASDAQ: BEAM), highlighting a weak near-term sentiment but long-term strength. It details specific AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report also offers key findings and signals based on a 95.0:1 risk-reward setup.
Assessing Beam Therapeutics (BEAM) Valuation After Positive AATD Regulatory Update
Beam Therapeutics (BEAM) has seen positive attention following a favorable regulatory update for its Alpha-1 Antitrypsin Deficiency program, with analysts viewing it as a crucial development for the company's pipeline. Despite recent share price momentum, the stock is currently trading around US$27.62, significantly below analyst targets of US$47.21 and a widely followed fair value narrative of $150 a share. This valuation gap suggests the market might be overlooking the future potential of its "one and done" therapy, BEAM-302, which has shown strong early clinical data.
Privium Fund Management B.V. Acquires Shares of 61,000 Beam Therapeutics Inc. $BEAM
Privium Fund Management B.V. has acquired a new stake of 61,000 shares in Beam Therapeutics (NASDAQ:BEAM) during Q3, valued at approximately $1.48 million. This purchase represents about 0.06% ownership in the company, which also saw an insider, Christine Bellon, sell 18,629 shares, reducing her holdings by 16.11%. Beam Therapeutics is highly institutionally owned at nearly 99.68%, with a consensus analyst rating of "Moderate Buy" and a target price of $43.80 despite recent EPS and revenue misses.
Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM)
Bernstein has reiterated its Outperform rating for Beam Therapeutics Inc. (BEAM), increasing its price target from $37 to $41, citing a favorable regulatory update for the company's Alpha-1 Antitrypsin Deficiency program. Separately, UBS initiated coverage on BEAM with a Neutral rating and a $28 price target. Both firms highlighted improving biotechnology fundamentals and upcoming milestones for Beam Therapeutics.
Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM)
Bernstein has maintained an Outperform rating on Beam Therapeutics Inc. (BEAM), increasing its price objective from $37 to $41, primarily due to a favorable regulatory update for the company's Alpha-1 Antitrypsin Deficiency program. The report also highlights upcoming milestones for Beam Therapeutics, including revised AATD data expected in Q1 2026. Separately, UBS initiated coverage of BEAM with a Neutral rating and a $28 price target, noting an overall improvement in biotechnology fundamentals.
Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM)
Bernstein has reiterated its Outperform rating on Beam Therapeutics Inc. (BEAM), increasing its price target from $37 to $41 due to a favorable regulatory update for the company's Alpha-1 Antitrypsin Deficiency program. UBS also initiated coverage of Beam Therapeutics with a neutral rating and a $28 price target, noting improving biotechnology fundamentals. The article highlights Beam as a biotechnology firm focused on precision genetic drugs.
BEAM: FDA Alignment And Upcoming Pulmonary Data Will Drive Bullish Repricing
Analyst price targets for Beam Therapeutics (BEAM) have increased, with the fair value estimate rising from US$45.92 to US$47.21. This bullish sentiment is driven by greater confidence in the company's FDA alignment for key programs, upcoming data for BEAM-302, and early progress on BEAM-103. Recent clinical data from the BEACON Phase 1/2 trial for risto cel in sickle cell disease also showed positive safety and efficacy, further contributing to the updated valuation.
Christine Bellon Sells 1,371 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock
Christine Bellon, an insider at Beam Therapeutics (NASDAQ:BEAM), recently sold 1,371 shares of the company's stock for a total of $46,614.00, reducing her position by 1.41%. This follows a previous sale of 18,629 shares earlier in January. Beam Therapeutics has shown a 32.2% year-over-year revenue decline, missing EPS and revenue estimates, although analysts maintain a "Moderate Buy" consensus rating with a target price of $43.80.
Did FDA Alignment on BEAM-302’s Accelerated Pathway Just Shift Beam Therapeutics' (BEAM) Investment Narrative?
Beam Therapeutics (BEAM) recently secured FDA alignment for an accelerated approval pathway for its BEAM-302 gene-editing program, targeting Alpha-1 Antitrypsin Deficiency. This development is seen as a significant de-risking event for BEAM-302 and could boost interest in Beam's base-editing platform. While the regulatory roadmap is clearer, investors should also consider the company's ongoing losses, unprofitability, insider selling, and potential cash needs, alongside widely varying fair value estimates from analysts.
Did FDA Alignment on BEAM-302’s Accelerated Pathway Just Shift Beam Therapeutics' (BEAM) Investment Narrative?
Recent FDA alignment on an accelerated approval pathway for Beam Therapeutics' BEAM-302 gene-editing program for Alpha-1 Antitrypsin Deficiency has de-risked the program and could attract broader pharmaceutical interest. This development clarifies the regulatory roadmap for one of Beam's leading in vivo programs and strengthens the investment narrative, although financial risks and insider selling remain. Investors should consider the company's cash needs and varying fair value estimates, which range widely among analysts.
Beam Therapeutics (NASDAQ:BEAM) Shares Down 7.6% - Here's Why
Beam Therapeutics (NASDAQ:BEAM) saw its shares drop 7.6% on Friday following a miss on both earnings and revenue expectations. The company reported EPS of ($1.10) against an expected ($0.98), with revenue down 32.2% year-over-year. Despite a generally positive "Moderate Buy" consensus from analysts, weak top-line trends and insider selling contribute to the stock's recent decline.
Cathie Wood Sells $5 Million Beam Therapeutics Stock, Buys WeRide and Tempus AI
Cathie Wood's ARK Invest has adjusted its portfolio, selling $5.03 million worth of Beam Therapeutics stock while increasing its stakes in autonomous driving company WeRide and healthcare data firm Tempus AI. The fund also reduced its holdings in Unity Software, Roku, and GitLab, indicating a shift towards AI and autonomous technology sectors and away from certain biotech and software companies.
SG Americas Securities LLC Purchases 36,004 Shares of Beam Therapeutics Inc. $BEAM
SG Americas Securities LLC significantly increased its stake in Beam Therapeutics Inc. by 498.9% in the third quarter, acquiring 36,004 additional shares to hold a total of 43,220 shares valued at approximately $1.05 million. This purchase contributes to institutional investors owning nearly all (99.68%) of the company's stock. Despite a "Moderate Buy" consensus from Wall Street analysts with an average target price of $44.23, Beam Therapeutics recently missed earnings expectations and reported negative margins.
Campbell & CO Investment Adviser LLC Lowers Stock Position in Beam Therapeutics Inc. $BEAM
Campbell & CO Investment Adviser LLC significantly reduced its stake in Beam Therapeutics Inc. by 92.7% in Q3, selling over 210,000 shares and retaining a smaller position. This comes as Beam Therapeutics missed Q3 earnings and revenue expectations, reporting an EPS of ($1.10) against an anticipated ($0.98), and revenue of $9.7 million versus $12.8 million. The stock, which is 99.7% institutionally owned, is currently trading up about 10.1% at $34.26, with analysts giving it an average "Moderate Buy" rating and a target price of $43.80.
Beam Therapeutics (BEAM) Valuation After FDA Alignment On Accelerated Pathway For BEAM-302
Beam Therapeutics (BEAM) is facing renewed investor interest after the FDA aligned on an accelerated approval pathway for its BEAM-302 program for alpha-1 antitrypsin deficiency. The stock has seen a significant 1-month return but still carries multi-year declines, trading below the average analyst price target. Its price-to-book ratio of 3.5x is above the US Biotech industry average, suggesting high expectations for future growth despite the company currently being loss-making.
Beam Therapeutics (NASDAQ:BEAM) Trading 11.1% Higher - What's Next?
Beam Therapeutics (NASDAQ:BEAM) saw its shares jump 11.1% on Thursday, trading as high as $35.34 before closing around $34.58, despite lower-than-average volume. The company faces weak fundamentals, including an EPS loss and missed revenue, and an insider recently sold a significant number of shares. Analysts maintain a "Moderate Buy" consensus with an average price target of $43.80, reflecting some optimism despite the financial performance.
Cathie Wood’s ARK ETFs Buy Netflix, Sell Beam Therapeutics in Latest Moves
Cathie Wood's ARK Invest ETFs made significant trades on January 21, 2026, buying $7.27 million in Netflix shares and $5.98 million in Tempus AI, while selling $4.19 million in Beam Therapeutics. The transactions reflect a strategic shift, increasing exposure to streaming and healthcare AI, and reducing stakes in certain biotech and software companies like GitLab and Pinterest. These moves highlight ARK's focus on high-growth technology sectors and dynamic portfolio adjustments.
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway By Investing.com
Bernstein has increased its price target for Beam Therapeutics (NASDAQ:BEAM) to $41.00 from $37.00, maintaining an Outperform rating, due to positive regulatory news regarding its BEAM-302 program for Alpha-1 Antitrypsin Deficiency. The firm's confidence stems from the company aligning with the FDA on an accelerated approval pathway for BEAM-302, which Bernstein views as a substantive development. This adjustment reflects higher risk-adjusted peak sales projections and Beam's improved cash balance, contributing to the belief that the stock is undervalued despite recent price volatility.
Insider Sell: Bethany Cavanagh Sells Shares of Beam Therapeutics Inc (BEAM)
Bethany Cavanagh, Senior Vice President of Finance and Treasurer at Beam Therapeutics Inc (BEAM), sold 3,034 shares of the company on January 20, 2026. Following this transaction, Cavanagh now owns 41,011 shares. The stock was trading at $30.12 at the time of the sale, and GuruFocus estimates it to be significantly overvalued with a price-to-GF-Value ratio of 3.54 compared to its GF Value of $8.51.
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway
Bernstein has increased its price target for Beam Therapeutics Inc (NASDAQ:BEAM) to $41 from $37, maintaining an Outperform rating, due to positive regulatory news regarding its BEAM-302 program. The FDA has aligned on an accelerated approval pathway for BEAM-302, intended for Alpha-1 Antitrypsin Deficiency (AATD), which Bernstein views as a significant development. Despite a recent stock dip, the firm sees a substantial gap between the current share price and its fair value, also noting the company's strong cash position.
Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway By Investing.com
Bernstein has increased its price target for Beam Therapeutics Inc (NASDAQ:BEAM) to $41 from $37, maintaining an Outperform rating, following the company's alignment with the FDA on an accelerated approval pathway for its BEAM-302 program. This updated target aligns with InvestingPro’s Fair Value assessment, indicating Beam Therapeutics is currently undervalued. The adjustment reflects Bernstein’s higher risk-adjusted peak sales projections for BEAM-302 and the company’s improved cash position.
Discipline and Rules-Based Execution in BEAM Response
This article provides an in-depth analysis of Beam Therapeutics Inc. (NASDAQ: BEAM) using AI models to suggest choppy market conditions and conflicting sentiments across different time horizons. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, highlighting support and resistance levels for near-term, mid-term, and long-term outlooks.
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) Insider Sells 18,629 Shares of Stock
Christine Bellon, an insider at Beam Therapeutics (NASDAQ:BEAM), sold 18,629 shares of the company's stock on January 15th, 2026, for approximately $644,750, reducing her stake by over 16%. This transaction occurred as Beam Therapeutics traded near $30.97 after missing its recent quarterly EPS and revenue estimates. Despite the insider selling, analysts maintain a "Moderate Buy" consensus rating with an average price target of $44.23 for the gene-editing company.
